Mesna
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DRUG-MESNA |
|---|---|
| Art | Arzneimittel |
| Aliase | Mesnex |
| Status | überprüft 2026-05-07 |
| Erkrankungen | DIS-BURKITT DIS-SOFT-TISSUE-SARCOMA |
| Quellen | SRC-ESMO-SARCOMA-2024 SRC-NCCN-STS-2025 |
Drug Facts
| Klasse | Uroprotektiv Thiol-Zytoprotektor |
|---|---|
| Verfahren | Thiol compound that binds and detoxifies urotoxic ifosfamide metabolites in urine, reducing the risk of hemorrhagic cystitis. It is supportive care, not an antineoplastic treatment-selection signal. |
| Typische Dosierung | With ifosfamide: commonly administered as a total daily mesna dose proportional to the ifosfamide dose, using IV and/or oral divided dosing according to institutional protocol. Maintain hydration and urine monitoring. |
| Ukraine registriert | Falsch |
| NSZU erstattet | Falsch |
Anmerkungen
Thin support-drug entity added to resolve ifosfamide-containing regimen component references. Regimen-specific mesna schedules remain authored on the regimen.
Verwendet von
Therapieschema
REG-CODOX-IVAC-PROVEN-CNS- eviQ proven-CNS R-CODOX-M / R-IVAC reference for specialist reviewREG-CODOX-M-IVAC- Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 44...REG-DOXORUBICIN-IFOSFAMIDE-STS- Doxorubicin + ifosfamide (Weichgewebesarkom, AI Behandlung)